SensoDetect (SDET) Q2 2025 earnings summary

Executive summary

• Achieved key milestones in Q2 2025, including presenting neurodiagnostic technology at a major ADHD congress, opening a new office near Karolinska Institutet, and launching ADHD/autism screening in Stockholm.

• Clinical progress in autism studies, AI initiative for commercialization, and interim results from Saudi Arabia ASD study.

• First revenues from China JV, with 300 KSEK in royalties; groundwork laid for rapid market entry in China.

• Set goal to capture 10% of the global ASD/ADHD diagnostics market, valued at €6.8 billion.

Financial highlights

• Q2 2025 net sales: 102 KSEK (vs. 4 KSEK Q2 2024); H1 2025 net sales: 222 KSEK (vs. 10 KSEK H1 2024).

• Q2 2025 net result: -2,507 KSEK (vs. -2,782 KSEK Q2 2024); H1 2025 net result: -4,455 KSEK (vs. -5,094 KSEK H1 2024).

• Cash flow from operations Q2 2025: -2,227 KSEK (vs. -1,843 KSEK Q2 2024); cash at period end: 8,158 KSEK (vs. 4,347 KSEK Q2 2024).

• Equity ratio as of June 30, 2025: 89% (vs. 81% June 30, 2024).

Outlook and guidance

• Positioned for accelerated international expansion, especially in China and Europe.

• Focus on scaling, profitable growth, and shareholder value creation in H2 2025.

• Ambition to become a global leader in psychiatric diagnostics.